文献速递胃肠外科肝胆胰外科围术期管理与 ERAS

熊去氧胆酸预防胃癌胃切除术后胆结石形成的随机临床试验

Efficacy and Safety of Ursodeoxycholic Acid for the Prevention of Gallstone Formation After Gastrectomy in Patients With Gastric Cancer: The PEGASUS-D Randomized Clinical Trial.
PubMed 文献 · JAMA Surg · 2020-01-01

PEGASUS-D 研究为多中心随机双盲安慰剂对照试验,纳入 521 例胃癌胃切除术后患者,比较熊去氧胆酸 300 mg、600 mg 与安慰剂每日服用 52 周的效果。全分析集显示,12 个月内胆结石发生率在 300 mg 组为 5.3%、600 mg 组为 4.3%、安慰剂组为 16.7%,UDCA 显著降低胆结石形成风险且未发现显著药物不良反应。

要点

  • 胃癌胃切除术后服用 UDCA 52 周可显著降低 12 个月内胆结石发生率。
  • 300 mg 与 600 mg 剂量均优于安慰剂,OR 分别为 0.27 和 0.20。
  • 研究中未检测到显著药物不良反应。

核心结论

  • 胃癌胃切除术后每日服用 UDCA 52 周可显著降低 12 个月内胆结石发生率。
  • UDCA 300 mg 和 600 mg 均优于安慰剂,且未发现显著药物不良反应。

研究设计与样本

  • PEGASUS-D 为在韩国 12 家机构开展的多中心、随机、双盲、安慰剂对照临床试验。
  • 纳入 521 例≥19 岁接受全胃、远端或近端胃切除术的胃癌患者,按 1:1:1 随机分配至 UDCA 300 mg、600 mg 或安慰剂组,每日服用 52 周。
  • 全分析集 465 例,其中 300 mg 组 151 例、600 mg 组 164 例、安慰剂组 150 例;主要终点为胃切除术后 12 个月内胆结石形成比例。

主要发现

  • 12 个月内胆结石形成比例:300 mg 组 8/151(5.3%),600 mg 组 7/164(4.3%),安慰剂组 25/150(16.7%)。
  • 与安慰剂相比,300 mg 组胆结石形成的 OR 为 0.27(95%CI 0.12-0.62;P=.002)。
  • 与安慰剂相比,600 mg 组胆结石形成的 OR 为 0.20(95%CI 0.08-0.50;P<.001)。
  • enrolled patients 中未检测到显著药物不良反应。

临床怎么用

  • 对胃癌胃切除术后患者,可考虑每日服用 UDCA 52 周以预防胆结石形成。
  • 300 mg 与 600 mg 剂量均显示有效,临床选择需结合患者具体情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The incidence of gallstones has been reported to increase after gastrectomy. However, few studies have been conducted on the prevention of gallstone formation in patients who have undergone gastrectomy. OBJECTIVE: To evaluate the efficacy and safety of ursodeoxycholic acid (UDCA) in preventing gallstone formation after gastrectomy in patients with gastric cancer. DESIGN, SETTING, AND PARTICIPANTS: The PEGASUS-D study (Efficacy and Safety of DWJ1319 in the Prevention of Gallstone Formation after Gastrectomy in Patient with Gastric Cancer: A Multicenter, Randomized, Double-blind, Placebo-controlled Study) was a randomized, double-blind, placebo-controlled clinical trial conducted at 12 institutions in the Republic of Korea. Adults (aged ≥19 years) with a diagnosis of gastric cancer who underwent total, distal, or proximal gastrectomy were enrolled between May 26, 2015, and January 9, 2017; follow-up ended January 8, 2018. Efficacy was evaluated by both the full analysis set, based on the intention-to-treat principle, and the per-protocol set; full analysis set findings were interpreted as the main results. INTERVENTIONS: Eligible participants were randomly assigned to receive 300 mg of UDCA, 600 mg of UDCA, or placebo at a ratio of 1:1:1. Ursodeoxycholic acid and placebo were administered daily for 52 weeks. MAIN OUTCOMES AND MEASURES: Gallstone formation was assessed with abdominal ultrasonography every 3 months for 12 months. Randomization and allocation to trial groups were carried out by an interactive web-response system. The primary end point was the proportion of patients developing gallstones within 12 months after gastrectomy. RESULTS: A total of 521 patients (175 received 300 mg of UDCA, 178 received 600 mg of UDCA, and 168 received placebo) were randomized. The full analysis set included 465 patients (311 men; median age, 56.0 years [interquartile range, 48.0-64.0 years]), with 151 patients in the 300-mg group, 164 patients in the 600-mg group, and 150 patients in the placebo group. The proportion of patients developing gallstones within 12 months after gastrectomy was 8 of 151 (5.3%) in the 300-mg group, 7 of 164 (4.3%) in the 600-mg group, and 25 of 150 (16.7%) in the placebo group. Compared with the placebo group, odds ratios for gallstone formation were 0.27 (95% CI, 0.12-0.62; P = .002) in the 300-mg group and 0.20 (95% CI, 0.08-0.50; P < .001) in the 600-mg group. No significant adverse drug reactions were detected among the enrolled patients. CONCLUSIONS AND RELEVANCE: Administration of UDCA for 12 months significantly reduced the incidence of gallstones after gastrectomy for gastric cancer. These findings suggest that UDCA administration prevents gallstone formation after gastrectomy in patients with gastric cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02490111.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Lee SH, Jang DK, Yoo MW, et al. Efficacy and Safety of Ursodeoxycholic Acid for the Prevention of Gallstone Formation After Gastrectomy in Patients With Gastric Cancer: The PEGASUS-D Randomized Clinical Trial. JAMA Surg. 2020. PMID: 32584935. doi:10.1001/jamasurg.2020.1501

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。